- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. To schedule a demo, contact us at sales@docketalarm.com or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 24-38 of
155 results
2032 Exhibit: Paul, GA, Bosentan decreases the plasma concentration of sildenafil...
Document
IPR2025-01139, No. 2032 Exhibit - Paul, GA, Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1053 Exhibit: EX 1053 Baylor Declaration
Document
IPR2025-01139, No. 1053 Exhibit - EX 1053 Baylor Declaration (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1052 Exhibit: EX 1052 Ravi Declaration
Document
IPR2025-01139, No. 1052 Exhibit - EX 1052 Ravi Declaration (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2020 Exhibit: Nielsen Kudsk, JE et al, K channel opening a new drug principle in ca...
Document
IPR2025-01139, No. 2020 Exhibit - Nielsen Kudsk, JE et al, K channel opening a new drug principle in cardiovascular medicine, (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2016 Exhibit: Declaration of Dr Luke Howard, DPhil MB BChir FRCP
Document
IPR2025-01139, No. 2016 Exhibit - Declaration of Dr Luke Howard, DPhil MB BChir FRCP (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2027 Exhibit: Rubin, LJ et al, Bosentan Therapy for Pulmonary Arterial Hypertensio...
Document
IPR2025-01139, No. 2027 Exhibit - Rubin, LJ et al, Bosentan Therapy for Pulmonary Arterial Hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1052 Exhibit: EX 1052 Ravi Declaration
Document
IPR2025-01139, No. 1052 Exhibit - EX 1052 Ravi Declaration (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2025 Exhibit: Schneider, MP et al, Contrasting Actions of Endothelin ETA and ETB ...
Document
IPR2025-01139, No. 2025 Exhibit - Schneider, MP et al, Contrasting Actions of Endothelin ETA and ETB Receptors in Cardiovascular Disease (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2017 Exhibit: Revatio® Label
Document
IPR2025-01139, No. 2017 Exhibit - Revatio® Label (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2031 Exhibit: Sica, DA Gehr, TWB, Direct Vasodilators and their Role in Hypertensi...
Document
IPR2025-01139, No. 2031 Exhibit - Sica, DA Gehr, TWB, Direct Vasodilators and their Role in Hypertension Management Minoxidil, J CLIN HYPERTENSION (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2026 Exhibit: Lee, SH Channick, RN, Endothelin Antagonism in Pulmonary Arterial ...
Document
IPR2025-01139, No. 2026 Exhibit - Lee, SH Channick, RN, Endothelin Antagonism in Pulmonary Arterial Hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2029 Exhibit: McLaughlin, V et al, Randomized study of adding inhaled iloprost to e...
Document
IPR2025-01139, No. 2029 Exhibit - McLaughlin, V et al, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
2030 Exhibit: Hoeper, M et al, Combining inhaled iloprost with bosentan in patients ...
Document
IPR2025-01139, No. 2030 Exhibit - Hoeper, M et al, Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1053 Exhibit: EX 1053 Baylor Declaration
Document
IPR2025-01139, No. 1053 Exhibit - EX 1053 Baylor Declaration (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
1050 Exhibit: EX 1050 Actelion Pending Litigation
Document
IPR2025-01139, No. 1050 Exhibit - EX 1050 Actelion Pending Litigation (P.T.A.B. Oct. 1, 2025)
|
|
Cite Document
